Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Wave Life Sciences (WVE) over the last 11 years, with Sep 2025 value amounting to -$12.2 million.

  • Wave Life Sciences' Net Cash Flow fell 107.79% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.6 million, marking a year-over-year decrease of 167.03%. This contributed to the annual value of $101.9 million for FY2024, which is 8.98% down from last year.
  • Per Wave Life Sciences' latest filing, its Net Cash Flow stood at -$12.2 million for Q3 2025, which was up 64.70% from -$34.6 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Net Cash Flow ranged from a high of $156.9 million in Q3 2024 and a low of -$88.8 million during Q1 2022.
  • Over the past 3 years, Wave Life Sciences' median Net Cash Flow value was -$19.3 million (recorded in 2024), while the average stood at $9.8 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 1,411.86% in 2022, then tumbled by 205.34% in 2025.
  • Over the past 5 years, Wave Life Sciences' Net Cash Flow (Quarterly) stood at $26.7 million in 2021, then slumped by 131.95% to -$8.5 million in 2022, then surged by 806.46% to $60.4 million in 2023, then slumped by 114.50% to -$8.8 million in 2024, then plummeted by 107.79% to -$12.2 million in 2025.
  • Its Net Cash Flow was -$12.2 million in Q3 2025, compared to -$34.6 million in Q2 2025 and -$59.0 million in Q1 2025.